Skip to main content
PCSA
NASDAQ Life Sciences

FDA Clears IND for Processa's VT-7208 Phase 2 CSU Trial

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.89
Mkt Cap
$5.177M
52W Low
$1.041
52W High
$10.843
52W Position info
82% above low
Off High info
83% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

PCSA sits 82% above its 52-week low of $1.041 on light trading volume (0.3× avg).

Summary

FDA cleared Processa's IND to start a Phase 2 study of VT-7208 in chronic spontaneous urticaria, a de-risking step for the lead asset, and the company plans Phase 2 studies in food allergy and relapsing multiple sclerosis as well. The company also disclosed a Generian FcRn research/option deal and named Sheila Gujrathi, M.D., Executive Chair. It has roughly $200M from its private placement and guides cash into 2H 2029, which covers planned Phase 2 readouts. This is an execution update following the Vidya merger and $200M PIPE closed in July 2026, with the S-3 resale registration and the November 30 reverse-split vote still pending. The next real test is Phase 2 data in CSU, food allergy or RMS; timelines and endpoints are not specified here.

At the time of this announcement, PCSA was trading at $1.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $1.04 to $10.84. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

PCSA - Latest Insights

PCSA
Nov 13, 2026, 5:10 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.86
Real-time Price: $1.86 info
Change: $0 (0%) info
Market Cap: $5.205M info
PCSA
Nov 05, 2026, 8:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.85
Real-time Price: $1.86 info
Change: +$0.010 (+0.54%) info
Market Cap: $5.205M info
PCSA
Oct 29, 2026, 8:46 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.95
Real-time Price: $1.86 info
Change: -$0.090 (-5%) info
Market Cap: $5.205M info
PCSA
Oct 09, 2026, 4:03 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $1.47
Real-time Price: $1.86 info
Change: +$0.390 (+27%) info
Market Cap: $5.205M info
PCSA
Oct 09, 2026, 4:02 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $1.47
Real-time Price: $1.86 info
Change: +$0.390 (+27%) info
Market Cap: $5.205M info